Novo Nordisk A/S
GLP-1 COMPOSITIONS AND USES THEREOF
Last updated:
Abstract:
The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
Status:
Application
Type:
Utility
Filling date:
28 Jan 2020
Issue date:
28 May 2020